Advanced Non Small Cell Lung Cancer Clinical Trial
Official title:
Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AZD9291 in Patients With Advanced Non Small Cell Lung Cancer Who Progressed on Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent
This study will treat patients with advanced NSCLC who have already received at least one course of specific anti-cancer treatment but the tumour has started to re-grow following that treatment. This is the first time this drug has ever been tested in patients, and so it will help to understand what type of side effects may occur with the drug treatment, it will measure the levels of drug in the body, it will also measure the anti-cancer activity. By using these pieces of information together the best dose of this drug to use in further clinical trials will be selected.
A Phase I/II, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Ascending Doses of AZD9291 in Patients with Advanced Non Small Cell Lung Cancer who have Progressed Following Prior Therapy with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent (AURA) ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03326752 -
Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC
|
Phase 1 | |
| Completed |
NCT02157883 -
Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)
|
Phase 1 | |
| Completed |
NCT00072631 -
Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT02163733 -
Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06107374 -
Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG
|
Phase 2 | |
| Recruiting |
NCT06406166 -
Lifei Xiaoji Wan in Treatment of Advanced NSCLC
|
N/A | |
| Terminated |
NCT04785365 -
Long-Term Follow-Up Study of Patients Receiving ATL001
|
Phase 2 | |
| Recruiting |
NCT04032847 -
ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC
|
Phase 1/Phase 2 | |
| Completed |
NCT01631136 -
Strategies for Maintenance Therapies in Advanced Non Small Cell Lung Cancer
|
Phase 3 | |
| Recruiting |
NCT04239443 -
Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer
|
Phase 2 | |
| Completed |
NCT03452150 -
D-0316 First Time in Patients Ascending Dose Study
|
Phase 1 | |
| Completed |
NCT04144608 -
Toripalimab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT04755738 -
Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT03652857 -
Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT03351361 -
Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients
|
Phase 3 | |
| Completed |
NCT02407327 -
Individualized Treatment of Patients With Advanced NSCLC: Potential Application for Circulating Tumor Cells (CTC) Molecular and Phenotypical Profiling
|
||
| Active, not recruiting |
NCT02143466 -
AZD9291 in Combination With Ascending Doses of Novel Therapeutics
|
Phase 1 | |
| Recruiting |
NCT05004974 -
Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT05777603 -
Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT04886401 -
Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patients With NSCLC
|